189 related articles for article (PubMed ID: 22391542)
1. Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens.
Snydman DR; Jacobus NV; McDermott LA
Antimicrob Agents Chemother; 2012 Jun; 56(6):3448-52. PubMed ID: 22391542
[TBL] [Abstract][Full Text] [Related]
2. In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species.
Citron DM; Tyrrell KL; Merriam CV; Goldstein EJ
Antimicrob Agents Chemother; 2012 Mar; 56(3):1613-5. PubMed ID: 22183166
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 gram-positive and gram-negative aerobic and anaerobic intestinal flora isolates.
Goldstein EJ; Citron DM; Tyrrell KL; Merriam CV
Antimicrob Agents Chemother; 2013 Oct; 57(10):4872-6. PubMed ID: 23877700
[TBL] [Abstract][Full Text] [Related]
4. Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faecium.
Mascio CT; Chesnel L; Thorne G; Silverman JA
Antimicrob Agents Chemother; 2014 Jul; 58(7):3976-82. PubMed ID: 24798273
[TBL] [Abstract][Full Text] [Related]
5. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.
Citron DM; Merriam CV; Tyrrell KL; Warren YA; Fernandez H; Goldstein EJ
Antimicrob Agents Chemother; 2003 Jul; 47(7):2334-8. PubMed ID: 12821492
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species.
Marchese A; Salerno A; Pesce A; Debbia EA; Schito GC
Chemotherapy; 2000; 46(4):253-66. PubMed ID: 10859431
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial properties of MX-2401, an expanded-spectrum lipopeptide active in the presence of lung surfactant.
Dugourd D; Yang H; Elliott M; Siu R; Clement JJ; Straus SK; Hancock RE; Rubinchik E
Antimicrob Agents Chemother; 2011 Aug; 55(8):3720-8. PubMed ID: 21576435
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile.
Mascio CT; Mortin LI; Howland KT; Van Praagh AD; Zhang S; Arya A; Chuong CL; Kang C; Li T; Silverman JA
Antimicrob Agents Chemother; 2012 Oct; 56(10):5023-30. PubMed ID: 22802252
[TBL] [Abstract][Full Text] [Related]
9. Effect of Surotomycin, a Novel Cyclic Lipopeptide Antibiotic, on Intestinal Colonization with Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice.
Deshpande A; Hurless K; Cadnum JL; Chesnel L; Gao L; Chan L; Kundrapu S; Polinkovsky A; Donskey CJ
Antimicrob Agents Chemother; 2016 Jun; 60(6):3333-9. PubMed ID: 26976870
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Clostridium difficile biofilms: imaging and antimicrobial treatment.
James GA; Chesnel L; Boegli L; deLancey Pulcini E; Fisher S; Stewart PS
J Antimicrob Chemother; 2018 Jan; 73(1):102-108. PubMed ID: 29029221
[TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.
Citron DM; Tyrrell KL; Merriam CV; Goldstein EJ
Antimicrob Agents Chemother; 2012 May; 56(5):2493-503. PubMed ID: 22290948
[TBL] [Abstract][Full Text] [Related]
12. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.
Peláez T; Alcalá L; Alonso R; Rodríguez-Créixems M; García-Lechuz JM; Bouza E
Antimicrob Agents Chemother; 2002 Jun; 46(6):1647-50. PubMed ID: 12019070
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital.
Aspevall O; Lundberg A; Burman LG; Akerlund T; Svenungsson B
Antimicrob Agents Chemother; 2006 May; 50(5):1890-2. PubMed ID: 16641471
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal colonization with a cephalosporinase-producing bacteroides species preserves colonization resistance against vancomycin-resistant enterococcus and Clostridium difficile in cephalosporin-treated mice.
Stiefel U; Nerandzic MM; Pultz MJ; Donskey CJ
Antimicrob Agents Chemother; 2014 Aug; 58(8):4535-42. PubMed ID: 24867962
[TBL] [Abstract][Full Text] [Related]
15. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection.
Nerandzic MM; Mullane K; Miller MA; Babakhani F; Donskey CJ
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S121-6. PubMed ID: 22752860
[TBL] [Abstract][Full Text] [Related]
16. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
Smith JR; Yim J; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of LY 264826 compared with that of vancomycin against 100 clinical isolates each of methicillin-resistant Staphylococcus aureus and Clostridium difficile.
Fasola EL; Moody JA; Gerding DN; Peterson LR
Antimicrob Agents Chemother; 1990 Oct; 34(10):2007-8. PubMed ID: 2291667
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of DS-2969b and comparator antimicrobial agents against Clostridioides (Clostridium) difficile, methicillin-resistant Staphylococcus aureus, and other anaerobic bacteria.
Tyrrell KL; Citron DM; Merriam CV; Leoncio E; Goldstein EJC
Anaerobe; 2018 Dec; 54():39-41. PubMed ID: 30096588
[TBL] [Abstract][Full Text] [Related]
19. Analysis of anti-Clostridium difficile activity of thuricin CD, vancomycin, metronidazole, ramoplanin, and actagardine, both singly and in paired combinations.
Mathur H; O'Connor PM; Hill C; Cotter PD; Ross RP
Antimicrob Agents Chemother; 2013 Jun; 57(6):2882-6. PubMed ID: 23571539
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of an automated ultraviolet radiation device for decontamination of Clostridium difficile and other healthcare-associated pathogens in hospital rooms.
Nerandzic MM; Cadnum JL; Pultz MJ; Donskey CJ
BMC Infect Dis; 2010 Jul; 10():197. PubMed ID: 20615229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
